🚨 New paper out in Advanced Science!
We used shear-activated nanoparticles to deliver nitroglycerin to brain collaterals — improving stroke outcomes without systemic side effects.
🧠💥 Targeted therapy for ischaemic stroke is here.
🔗 https://t.co/vwXfG7gdTQ
Really enjoyed participating in this great event!! Thanks to @NSWCVRN rising stars sub-committee for organising. Stoked to have won the EMCR category. The quality of the pitches from all participants was outstanding!
Congratulations to the winners of the @NSWCVRN HEART Pitch 2024!
PhD Category
Winner: Tejas Deshmukh
People’s choice: Kate Drury
EMCR Category
Winner: Daniel Beard
Peoples choice: Dashika Palipana
Congratulations to the winners of the @NSWCVRN HEART Pitch 2024!
PhD Category
Winner: Tejas Deshmukh
People’s choice: Kate Drury
EMCR Category
Winner: Daniel Beard
Peoples choice: Dashika Palipana
3. These findings strongly suggest that rapamycin may be a useful therapy for improving #microvascular#reperfusion and be a an adjunct treatment to improve the effectiveness of recanalization therapies in ischaemic stroke.
Excited to share that our work showing the #mTOR inhibitor #rapamycin (Sirolimus) can reduce #brain#pericyte constriction following #stroke, is now published in Translational Stroke Research! https://t.co/4ZPiiKKf5o
2. In mice undergoing #MCAO and reperfusion, rapamcyin treatment significantly increased the diameter of #capillaries at pericyte locations as well as increased the proportion of capillaries that were patent (open) vs those completely constricted (closed) at pericyte locations.
Huge thanks to all co-authors on this collaborative effort. @DrLachlanSBrown @Gazz4_Science @dr_yvonne_couch @CSKarali@BradASutherland Twiterless/Xless: Bryan Adriaanse Anna Schneider, David Howells, Zoran Redzic and Alastair Buchan.
Numerous pharmacological studies modulating pericyte contraction are currently being published! 👀
This interesting @biorxivpreprint shows that #Rapamycin (#mTOR inhibition) relaxes #pericytes, mitigating capillary dysfunction after stroke reperfusion 🧠
https://t.co/m555pRjAdj
@Ella_Maru we assessed the effects 30min after reperfusion, so not sure what the long term effects would be. However colleagues have shown that activation of mTOR out past 4 weeks post-stroke is beneficial. So timing of rapamycin adminsitration is critical.
Excited to share our new preprint showing that the #mTOR inhibitor #rapamycin (Sirolimus) can reduce #brain#pericyte constriction following ischemia in vitro and #MCAO#stroke in vivo. https://t.co/xAxfD2f2Io.
@MattDun17 We haven’t, but should. We focused on sirolimus as it has the most evidence behind it in terms of a cerebrovascular protective effect in stroke models. However, there is emerging evidence of the benefits of everolimus in stroke models also.
Huge thanks to all co-authors on this collaborative effort. @DrLachlanSBrown @Gazz4_Science @dr_yvonne_couch @CSKarali@BradASutherland Twiterless/Xless: Bryan Adriaanse Anna Schneider, David Howells, Zoran Redzic and Alastair Buchan.
4. These findings strongly suggest an anti-contractile effect of rapamycin in vivo following stroke and thus rapamycin may be a useful therapy for improving microvascular reperfusion following recanalization therapies in ischaemic stroke.
Interested in learning more about the heart and stroke research being done in the Hunter? Interested in learning more about how you can engage in more meaningful consumer involvement at every stage of the research pipeline? Register now for this free event https://t.co/A6ynix0Bvt
Thrilled to be promoted to Senior Lecturer @Uni_Newcastle @UON_research commencing in January 2024!! Thanks to all my wonderful colleagues who have supported me along this journey. #stroke#EMCR